Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...atment...
...commendations on Extended Therapy...
...with node-negative breast cancer ar...
...ode-positive breast cancer should be off...
...ing extended adjuvant endocrine the...
...s prevention of secondary or contralateral breast...
...xtended therapy carries ongoing risks and side...
...mmendations on Ovarian Suppression...
...ommends that higher risk patients s...
...e II or Stage III breast cancers who would ordinar...
...omen with Stage I or II breast cancers at...
...en with Stage I breast cancers not...
...th node-negative cancers 1 centimete...
...varian suppression may be administered w...
...commended Pharmaceuticals for HR+ Breast Cancer...
...gnostic Factors for Recurrence After 5 Yea...